Liver transplantation in recipients over 65 yr old: a single center experience.

INTRODUCTION: The advanced age of the recipient is considered a "relative contraindication" to liver transplantation (LT). However, recently some studies reported a morbidity rate and an overall survival comparable with those of younger patients. Here, we reported the outcome after LT in recipients aged >65 yr. METHODS: Between January 2000 and December 2006, 565 LT was performed in 502 recipients in our institution. Of these, 34 were recipients of >65 yr old (aged group). We focused our study comparing: donor age, co-morbidities, model for end-stage liver disease (MELD) and American Society of Anesthesiologists (ASA) score, duration of operation, transfusions and outcome between the two groups (young/aged). RESULTS: For the group aged >65: the mean donor age was 52.5 (range 16-75) yr and the graft weight 1339 g (890-1880 g). Co-morbidity was recorded in 25 (73.5%), coronary artery disease (CAD) in 17 (50%), diabetes mellitus (DM) and chronic renal insufficiency in four (11.7%) and chronic obstructive pulmonary disease (COPD) in three patients (8.8%). Mean MELD score was 14.9 (range 12-29) and ASA score was two in 15 (44.1%); and three in 19 (55.8%) recipients. Mean operation time was four h 45 min, three patients also received combined kidney transplantation. Twenty-five (73.5%) recipients received blood transfusions (mean 3.2). Morbidity was observed in 20 patients (58.8%); of these two had hepatic artery thrombosis requiring re-LT. Overall survival was 80% (40 months of follow-up), in particularly, at 30-d, one yr, three yr was 91%, 84%, 80%, respectively. The only two statistical differences reported (p = 0.02) are: the lower rate of CAD in the younger group of recipients (12%), compared with the aged group (50%) and the subsequently lower mortality rate secondary to cardiac causes in the younger group (1.4%) compared with aged group (8.8%). CONCLUSION: Our results suggest that the recipient age should not be considered an absolute contraindication for LT when the graft/recipient matching is optimal and when an adequate cardiac assessment is performed.

Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort.

OBJECTIVE: To assess the impact of postmenopausal hormone use on the risk of stroke incidence and stroke mortality. DESIGN: Longitudinal study consisting of three data collection waves. The average follow up for cohort members was 11.9 years (maximum, 16.3 years). Cox proportional hazards regression models were used to estimate the relative risk of stroke for postmenopausal hormone ever-users compared with never-users. PARTICIPANTS: A national sample of 1910 (of 2371 eligible) white postmenopausal women who were 55 to 74 years old when examined in 1971 through 1975 as part of the first National Health and Nutrition Examination Survey and who did not report a history of stroke at that time. MAIN OUTCOME MEASURE: The main outcome measure was incident stroke (fatal and nonfatal). Events were determined from discharge diagnosis information coded from hospital and nursing home records and cause of death information coded from death certificates collected during the follow-up period (1971 through 1987). RESULTS: There were 250 incident cases of stroke identified, including 64 deaths with stroke listed as the underlying cause. The age-adjusted incidence rate of stroke among postmenopausal hormone ever-users was 82 per 10,000 woman-years of follow-up compared with 124 per 10,000 among never-users. Postmenopausal hormone use remained a protective factor against stroke incidence (relative risk, 0.69; 95% confidence interval, 0.47 to 1.00) and stroke mortality (relative risk, 0.37; 95% confidence interval, 0.14 to 0.92) after adjusting for the baseline risk factors of age, systolic blood pressure, diabetes, body mass index, smoking, history of hypertension and heart attack, and socioeconomic status. CONCLUSIONS: The results suggest that postmenopausal hormone use is associated with a decrease in risk of stroke incidence and mortality in white postmenopausal women.

Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort.

A national sample of 1944 white menopausal women greater than or equal to 55 years old from the epidemiologic follow-up of participants in the National Health and Nutrition Examination Survey was reviewed to investigate the role of hormone therapy in altering the risk of death from cardiovascular disease. Women in the study were observed for up to 16 years after the baseline survey in 1971 to 1975. By 1987 631 women had died; 347 of these deaths were due to cardiovascular disease. History of diabetes (relative risk, 2.38; 95% confidence interval 1.73 to 3.26), previous myocardial infarction (relative risk, 2.12; 95% confidence interval 1.56 to 2.86), smoking (relative risk, 2.18; 95% confidence interval, 1.69 to 2.81), and elevated blood pressure (relative risk, 1.49; 95% confidence interval, 1.14 to 1.94) were strong predictors of cardiovascular disease-related death in this cohort. After adjusting for known cardiovascular disease risk factors (smoking, cholesterol, body mass index, blood pressure, previous myocardial infarction, history of diabetes, age) and education, the use of postmenopausal hormones was associated with a reduced risk of death from cardiovascular disease (relative risk, 0.66; 95% confidence interval, 0.48 to 0.90). The same protective effect provided by postmenopausal hormone therapy was seen in women who experienced natural menopause (relative risk, 0.69; 95% confidence interval, 0.45 to 1.06).

HIV risk difference between condom users and nonusers among U.S. heterosexual women.

Using data from the National Survey of Family Growth, we estimate that among 3,498,060 U.S. reproductive-age women least likely to be protected from HIV, 12% rely on condoms for birth control. We have modeled the risk difference between condom users and nonusers and projected the number of preventable and nonpreventable HIV infections likely to occur among the 419,201 condom users as a function of 50 HIV-incidence/relative risk assumptions. Results of the attributable-risk model suggest that at the current low HIV-incidence level in U.S. women, condom-user failure rates will be less than 1% per year, substantially lower than the 10% condom-user failure rate for pregnancy. As few as 1% but up to 11% of all new HIV cases may be prevented by the current low level of condom use, depending on the exact degree of condom effectiveness in this population at risk. However, the model further projects that up to 45% of all new HIV cases may be prevented if condoms are maximally effective and far more widely used. Women with seropositive partners may enjoy the same protective benefits of condoms, but the costs in terms of condom-user failures will be much higher than in the remainder of the population at risk. Among serious and reliable users, condom-user failure rates for HIV may approach those for pregnancy, but only in women who have known seropositive partners.

Nonmenstrual toxic shock syndrome associated with barrier contraceptives: report of a case-control study.

Use of barrier contraceptives has been hypothesized to be a risk factor for nonmenstrual toxic shock syndrome (TSS). This association was evaluated in a case-control study of nonmenstrual TSS; cases were identified through an active surveillance system for TSS during 1986 and 1987. Potential risk factors for nonmenstrual TSS were compared for 28 patients and 100 age-matched controls. Use of barrier contraceptives was associated with a significantly increased risk of nonmenstrual TSS, with matched odds ratios of 10.5 and 11.7 for contraceptive sponge and diaphragm use, respectively. Use of nonbarrier contraceptive methods was unrelated to nonmenstrual TSS. Despite the elevated odds ratio, the incidence of nonmenstrual TSS in barrier contraceptives users and the risk of nonmenstrual TSS attributable to barrier contraceptive use are low. Clinicians and women who use barrier contraceptives should be aware of this rare but potentially fatal complication; however, other considerations, such as efficacy and complications associated with other types of contraception, may be more important in the choice of a contraceptive method.

Cardiovascular risk factors, premature heart disease, and all-cause mortality in a cohort of northern California women.

Large prospective studies and intervention trials have identified major risk factors for premature heart disease in men, while the Framingham Heart Disease Study has provided the leading evidence of predictors of cardiovascular disease in women. We evaluated the role of these risk factors in a 13-year follow-up study of 8935 premenopausal and 2716 postmenopausal women in the Walnut Creek Contraceptive Drug Study cohort in Northern California. Elevated cholesterol levels, high blood pressure, smoking, obesity, family history of heart disease, and diabetes were investigated for their contribution to premature death due to all causes and due to cardiovascular disease. In addition, risk factor profiles were developed separately for users and nonusers of Premarin (conjugated estrogen) in the postmenopausal cohort. The results show that the strongest predictors of cardiovascular mortality among premenopausal women were smoking, high blood pressure, and diabetes, with relative risks of 2.8, 10.5, and 11.6, respectively. A disparity between high cardiovascular risk factor prevalence and low rates of premature heart disease indicates that the high relative risks will not be accompanied by large attributable risks. Nevertheless, the study reconfirms the need for screening women for heart disease risk because life-style changes can improve cardiovascular risk factors and can potentially reduce the chance of premature death even further.

Midtrimester amniotic fluid delta optical density at 450 nm in normal pregnancies.

Spectrophotometric analysis of amniotic fluid has become the standard for assessing the fetal condition in Rh-immunized pregnancies. Serial amniocentesis is usually started at 28 to 29 weeks of gestation unless the antibody titer or history indicates it should be done earlier. This study presents the values from 14 to 20 weeks in normal pregnancies, which will also assist in evaluating pathologically elevated values.

Effects of halothane on the intramyocardial pressure of the canine left ventricle.

In the intact canine heart a gradient of systolic intramyocardial pressure from a minimum at the epicardial region to a maximum at the endocardial region is well established. No information is, however, available regarding the effects of various anaesthetic agents on this gradient. In the present study the effects of halothane on intramyocardial pressure recorded from subendocardial and subepicardial layers of the canine left ventricular free wall were assessed. Experiments were performed on seven anaesthetised mongrel dogs ventilated with 100% oxygen. Intramyocardial pressure was recorded simultaneously from the inner and outer regions of the myocardium using two Mikro-tip pressure transducers. Halothane concentration in the inspired gas varied from 0% to 2%. In the pentobarbital anaesthetised dog halothane does not significantly change the heart rate. With increasing concentrations of halothane in inspired gas systolic intramyocardial pressure at both endocardium and epicardium decreased significantly from control values. As the halothane concentration increased, the normal differential between systolic left ventricular pressure and endocardial intramyocardial pressure was abolished. The intramyocardial pressure gradient from endocardium to epicardium, however, persisted during systole. During diastole the pressure gradient was reversed, becoming maximum in the epicardial region and minimum in the endocardial region in both control and halothane treated animals. Over the range of 0-2% halothane concentration there was no significant effect on the diastolic intramyocardial pressure gradient. These results suggest that halothane affects the myocardial tissue pressure non-uniformly across the left ventricular free wall and therefore influence sth e transmural distribution of coronary blood flow.(ABSTRACT TRUNCATED AT 250 WORDS)

Halothane effects on subendocardial oxygen supply-demand balance: estimation from intramyocardial tissue pressure and left ventricular pressure.

We evaluated the effect of halothane on the balance of subendocardial oxygen supply and demand in six dogs by estimating the endocardial viability ratio (EVR) based on the pressure generated within the subendocardium (ENDO-IMP). Concurrently, the conventional EVR based on left ventricular pressure (LVP) was estimated and compared with the EVR based on ENDO-IMP. The subendocardial oxygen supply-demand ratio based on ENDO-IMP (IMP-EVR) was significantly less than EVR based on LVP (LVP-EVR) (0.87 +/- 0.03 vs 1.07 +/- 0.06, P less than 0.05) during the control period. With 0.5% halothane administration, IMP-EVR improved significantly (1.04 +/- 0.07, P less than 0.05) while LVP-EVR remained unchanged (1.08 +/- 0.09). No further changes in EVR (either IMP-EVR or LVP-EVR) were observed with increasing halothane concentrations up to 2%. The relationship between the two indices was weak (r2 = 0.44, P less than 0.001) but statistically significant. Because an estimate of EVR based on direct measurement of subendocardial tissue pressure (IMP-EVR) would reflect more accurately the oxygen supply-demand balance of this region than the LVP-EVR, our results suggest that the oxygen balance of the subendocardium improves with halothane administration. The use of LVP-EVR as a hemodynamic index of subendocardial oxygen balance during halothane anesthesia, therefore, is questionable.

Mortality among automobile assembly workers. II. White males.

The objective of this study was to examine the cause-specific mortality experience of white male employees from 10 assembly plants of five participating companies. Proportionate mortality ratio (PMR) analyses carried out using both national and local standards of comparison yielded similar results. Statistical significance of PMRs was assessed using the Mantel-Haenszel procedure. Statistically significant PMRs were observed for several causes of death when results for all plants were combined. However, the pattern of significant PMRs observed when results were analyzed separately by company and plant suggests that potential increases in risk for any individual cause of death are limited to no more than two companies and are not observed throughout the industry.

Lymphocytic leukemia and exposures to benzene and other solvents in the rubber industry.

Previous epidemiological studies on one cohort of rubber industry workers indicated that observed mortality excesses from lymphocytic leukemia were related to solvent exposures. The results of a detailed examination of the solvent exposure histories of 15 cases of lymphocytic leukemia from this cohort and 30 matched industry controls are presented. Extensive review of historical solvent use, raw materials specifications and job description records were used to reconstruct exposures to specific agents. Cases were 4.5 times as likely as controls to have had direct exposures to both benzene and other solvents. Analysis by manufacturing production source of solvent revealed that cases spent greater proportions of their work experience in jobs with potential exposures to coal tar-based benzene and xylene. No differences were seen for petroleum-derived solvents.

A case-control study of leukemia in the U.S. rubber industry.

A matched case-control study was conducted for 72 cases of leukemia occurring among employees of four rubber and tire manufacturing companies during the period from 1964 to 1973, to determine if certain environmental exposures were related to the risk of developing leukemia. Earlier studies conducted in one company had shown an association of lymphatic leukemia with a work history of possible solvent exposure, and the results of the present study suggest that the association is weaker than previously described. However, recently acquired detailed environmental information reported elsewhere tends to support the initial finding at this company. Further studies are required to fully resolve this issue. A finding was the lack of association in the order three companies. In addition, lymphatic leukemia was found to be associated with work experience in general service jobs for the two larger companies from which a majority (89%) of the cases derive. Intervals from exposure death peaked at 27 to 38 years. No elevated risk for myeloid leukemia was found.

Mortality among automobile assembly workers. I. Spray painters.

The primary objective of this study was to determine whether there was an increased mortality, especially with respect to cancer of the lung, among spray painters in the automobile manufacturing industry. The study was carried out at ten assembly plants from five participating companies and utilized both proportionate mortality ratio (PMR) and case-control analyses. Among workers with spray-painting experience, there were no statistically significant PMRs for lung cancer, either for all companies combined or for any company individually. In addition, the case-control analyses did not demonstrate a statistically significant excess risk for lung cancer mortality, adjusting for length of employment and duration in spray painting. The case-control analysis was large enough to detect approximately a two-fold increase if, in fact, an increase that large actually existed.